@article{fdi:010063887,
  title = {{E}fficacy of chloroquine for the treatment of {P}lasmodium vivax in the {S}aharan zone in {M}auritania},
  author = {{O}uld {A}hmedou {S}alem, {M}. {S}. and {L}emine, {Y}. {O}. {M}. and {D}eida, {J}. {M}. and {L}emrabott, {M}. {A}. {O}. and {O}uldabdallahi, {M}. and {B}a, {M}. {D}. {D}. and {O}uld {M}ohamed {S}alem {B}oukhary, {A}. and {K}hairy, {M}. {L}. {O}. and {A}ziz, {M}. {B}. {A}. and {R}ingwald, {P}ascal and {B}asco, {L}eonardo and {N}iang, {S}. {D}. and {L}ebatt, {S}. {M}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {I}n 2006, the {M}auritanian {M}inistry of {H}ealth adopted a new therapeutic strategy based on the systematic use of artemisinin-based combination therapy ({ACT}), artesunate-amodiaquine and artemether-lumefantrine, for the first-and second-line treatment of uncomplicated malaria, respectively, regardless of {P}lasmodium spp. {I}n the {S}aharan zone of the country, recent studies have shown that {P}lasmodium vivax largely predominates over {P}lasmodium falciparum. {A}nti-malarial drug response of {P}. vivax has not been evaluated in {M}auritania. {T}he aim of the present study was to evaluate the clinical efficacy and tolerance of chloroquine to treat {P}. vivax malaria in {M}auritanian patients. {M}ethods: {P}lasmodium vivax-infected patients aged > 6 months old were enrolled in {N}ouakchott and {A}tar in {S}eptember-{O}ctober 2013. {C}hloroquine was administered at the standard dose of 25 mg base/kg body weight over three days. {P}atients were followed until day 28, according to the standard 2009 {W}orld {H}ealth {O}rganization protocol. {R}esults: {A} total of 128 patients (67 in {N}ouakchott and 61 in {A}tar) were enrolled in the study. {S}even patients (5.5%) were either excluded or lost to follow-up. {B}ased on the per protocol analysis, chloroquine efficacy (adequate clinical and parasitological response) was 100%. {T}reatment was well-tolerated. {O}ne patient was excluded on day 1 due to urticaria and treated with artesunate-amodiaquine. {C}onclusions: {A}lthough the current national treatment guideline recommends artesunate-amodiaquine for the first-line treatment of uncomplicated malaria, including {P}. vivax malaria, chloroquine may still have an important role to play in anti-malarial chemotherapy in {M}auritania. {F}urther epidemiological studies are required to map the distribution of {P}. vivax and {P}. falciparum in the country.},
  keywords = {{D}rug resistance ; {P}lasmodium vivax ; {A}rtemisinin ; 4-aminoquinolines ; {C}linical trial ; {MAURITANIE} ; {SAHARA}},
  booktitle = {},
  journal = {{M}alaria {J}ournal},
  volume = {14},
  numero = {},
  pages = {art. 39 [5 p.]},
  ISSN = {1475-2875},
  year = {2015},
  DOI = {10.1186/s12936-015-0563-0},
  URL = {https://www.documentation.ird.fr/hor/fdi:010063887},
}